A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells  by Chiosis, Gabriela et al.
Research Paper
A small molecule designed to bind to the adenine nucleotide pocket
of Hsp90 causes Her2 degradation and the growth arrest and
di¡erentiation of breast cancer cells
Gabriela Chiosis*, Merna N. Timaul, Brian Lucas, Pamela N. Munster,
Fuzhong F. Zheng, Laura Sepp-Lorenzino 1, Neal Rosen
Program in Cell Biology and Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA
Received 6 November 2000; revisions requested 26 January 2001; revisions received 14 February 2001; accepted 22 February 2001
First published online 7 March 2001
Abstract
Background: The Hsp90s contain a conserved pocket that binds
ATP/ADP and plays an important role in the regulation of
chaperone function. Occupancy of this pocket by several natural
products (geldanamycin (GM) and radicicol) alters Hsp90
function and results in the degradation of a subset of proteins
(i.e. steroid receptors, Her2, Raf). We have used the structural
features of this pocket to design a small molecule inhibitor of
Hsp90.
Results : The designed small molecule PU3 competes with GM
for Hsp90 binding with a relative affinity of 15^20 WM. PU3
induces degradation of proteins, including Her2, in a manner
similar to GM. Furthermore, PU3 inhibits the growth of breast
cancer cells causing retinoblastoma protein hypophosphorylation,
G1 arrest and differentiation.
Conclusions: PU3 is representative of a novel class of synthetic
compounds that binds to Hsp90 and inhibits the proliferation of
cancer cells. These reagents could provide a new strategy for the
treatment of cancers. ß 2001 Elsevier Science Ltd. All rights
reserved.
Keywords: Her2; Hsp90 inhibitor; Novel anti-tumor agent; Geldanamy-
cin
1. Introduction
The Hsp90 family of chaperones is comprised of four
known members: Hsp90 K, Hsp90 L, Grp94 and Trap-1.
Hsp90 is an abundant cellular chaperone required for the
ATP-dependent refolding of denatured or ‘unfolded’ pro-
teins and for the conformational maturation of a variety
of key proteins involved in the growth response of the cell
to extracellular factors. These include the steroid receptors
as well as the Raf serine kinase and some tyrosine kinases
[1^7]. Hsp90 is also thought to play a role in maintaining
the stability and function of mutated proteins. It seems to
be required for the expression of mutated p53 and v-src,
but is required to a much lesser extent or not at all for
their wild-type counterparts [8,9].
Hsp90s have been shown to be overexpressed in multi-
ple tumor types and as a function of oncogenic transfor-
mation [10]. Although mutational analysis suggests that
Hsp90 is essential for eukaryotic cell survival, cancer cells
seem to be especially sensitive to short-term pharmacolog-
ical interference with the chaperone’s activity suggesting
that Hsp90s may be a novel target for anti-cancer drug
development [11].
The Hsp90 family members possess a unique pocket in
their N-terminal region that is speci¢c to and conserved
among all Hsp90s from bacteria to mammals, but is not
present in other molecular chaperones [12]. The pocket
binds ATP and ADP with low a⁄nity and has weak ATP-
ase activity [13]. The bent shape adopted by the nucleo-
tides when inside this pocket is very peculiar and is not
observed in other chaperones known to have ATP/ADP
pockets. However, in the somewhat structurally homolo-
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gous proteins DNA gyrase and MutL, the adenine nucleo-
tides adopt a similar conformation.
The ansamycin antibiotics geldanamycin and herbimy-
cin (GM, HA) and radicicol (RD) (Fig. 1) (originally iso-
lated on the basis of their ability to cause the reversion of
cells transformed by the v-src protooncogene) were also
determined to bind to this Hsp90 pocket, with much high-
er a⁄nities than the adenine nucleotides [14^16].
The last step in the refolding of a protein is its ATP-
dependent dissociation from Hsp90 and other chaperones
involved in the process. ADP inhibits the formation of the
complex, locking the protein in a di¡erent conformation.
It is therefore suggested that the nucleotide functions as a
molecular switch regulating two opposing conformational
states of Hsp90. The inhibitors seem to be mimicking the
ADP-bound state. Occupancy of the pocket by the natural
products prevents the dissociation of the proteins from the
chaperone complex and as a consequence, the trapped
proteins do not achieve their mature functional conforma-
tion. Instead they undergo ubiquitin-dependent degrada-
tion in the proteasome [1^7].
Addition of ansamycins to cells induces the proteasomal
degradation of a small subset of proteins involved in sig-
nal transduction. These include the steroid receptors and
Raf kinase, as well as certain transmembrane tyrosine ki-
nases. Of these, the Met and Her2 tyrosine kinases are
among the most sensitive targets described. In addition,
GM causes the selective degradation of certain proteins
that undergo mutation in cancer, such as v-src, bcr-abl
and p53, but has little or no e¡ect on their normal coun-
terparts. Most cellular proteins are una¡ected by the drugs
[1^7].
Since the Hsp90 chaperones are the only proteins shown
to directly interact with GM, HA and RD it is likely that
their biologic e¡ects are due to binding to these proteins.
Drugs that target Hsp90 in cancer cells and therefore stim-
ulate depletion of oncogenic proteins could be of clinical
bene¢t. 17-Allylamino-GM (17AAG) is currently in Phase
I clinical trial at several institutions including ours. How-
ever, its relative insolubility makes it di⁄cult to formulate
and administer. It is not easily synthesized and currently
must be generated by fermentation. The dose limiting tox-
icity of ansamycins is hepatic and may be secondary to the
nucleophilicity of the quinone and not to its binding to
Hsp90. Additionally, Hsp90 is a family of at least four
known members, which contain homologous but not iden-
tical N-terminal ATP/ADP binding pockets. These pro-
teins are likely to have speci¢c biological roles and it is
possible that the e¡ects of GM and RD are a sum of
unselective binding to all the family members. Molecules
that could di¡erentiate among the four proteins would
thus constitute important tools for the study of their in-
dividual functions and could have selective activity against
speci¢c cancers. In order to evaluate such possibilities
we set out to develop a soluble and easily synthesizable
small molecule that binds to the Hsp90 pocket and shares
biological activity with GM and RD. Once this goal is
achieved, the structure could be used for the develop-
ment of selective Hsp90 inhibitors with speci¢c cellular
e¡ects.
2. Results and discussion
2.1. Design of the Hsp90 inhibitor
A detailed study of the mode of binding of GM (Protein
Data Bank code 1YET), RD (code 1BGQ) and ADP
(code 1AMW) to the Hsp90 N-terminal ADP/ATP bind-
ing site revealed several important factors to be considered
in designing a molecule that would interact with this pock-
et: (1) a key interaction between the inhibitor and the
Asp93/Ser52 at the base of the pocket, (2) interactions at
the top involving Lys112, Lys58 and hydrogen acceptor
functionalities on the inhibitor, (3) a hydrophobic pocket
that lies midway in the binding site and that is constituted
by Met98, Val150, Leu107, Leu103, Phe138 and Val186
(the amino acid numbering as in human Hsp90 K). Addi-
tionally, the inhibitor should adopt a folded (C-shaped)
conformation even in the free state. A structure with min-
imal structural changes from unbound to complexed state
should not pay much entropic penalty and binding would
be predominantly determined by enthalpic factors. Lastly,
but not least important, the molecule should have a higher
a⁄nity than ADP for Hsp90.
More than 10% of the proteins encoded by the yeast
genome depend on purine-containing ligands for their
function. It is therefore expected that diverse purine libra-
ries would yield bioactive compounds with good solubility
Fig. 1. Structural representation of the known Hsp90 inhibitors.
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and cell permeability. Selectivity for one protein over an-
other should be achievable by correspondingly functional-
izing the skeleton, which is easily carried out in this class
of molecules due to the signi¢cant possibilities of perform-
ing chemistry on the purine skeleton. Although the ¢rst
and second sets of interactions mentioned above are con-
served in the homologous pockets of DNA gyrase and
MutL, the components of the pocket wall and hydropho-
bic pocket are entirely di¡erent. This fundamental di¡er-
ence makes it possible to design purine derivatives selec-
Fig. 2. Structures of the designed Hsp90 inhibitor PU3 and of two control compounds PU3R and Ad-But.
Fig. 3. (A) Crystal structure of GM bound to Hsp90 (ID code 1YET). (B) Structure of PU3 docked into the same pocket. (C) Crystal structure of
PU3. The protein backbone is represented in blue, while for the inhibitors the carbon backbone is drawn in gray, N atoms in blue and O atoms in red.
(D) Superimposed representation of GM and the modeled PU3 in the ADP binding pocket of Hsp90 K. Important interactions shared by the two mole-
cules with the pocket are represented in black. GM = red, PU3 = blue.
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tive for the several homologous pockets, since the size and
nature of the purine 9-N-alkyl can be easily modi¢ed.
Based on all of the above observations we theoretically
designed the molecule PU3 (Fig. 2) and docked the struc-
ture into the Hsp90 K ADP/ADP binding site. The mole-
cule showed a good theoretical ¢t and ful¢lled all of the
important interactions with the protein pocket (Fig. 3B).
At the top, the Lys112 interacts with two of the methoxy
groups on the phenyl moiety, the butyl chain occupies the
described hydrophobic pocket, while at the base, Asp93
and Ser52 are hydrogen-bound to the purine NH2. The
structure of the molecule was determined by X-ray crys-
tallography and is very similar to the one determined by
computer modeling, suggesting that PU3 adopts a folded
shape in both the free and bound states (Fig. 3C). GM
crystallizes from organic solvents in signi¢cantly more
open, extended conformation [17] which according to
Roe et al. [16] accounts for weaker binding a⁄nity of
GM compared to RD, a molecule that binds to Hsp90
in the conformation observed in the free crystal state.
PU3 occupies most of the pocket ¢lled by GM and
extends more deeply into the hydrophobic wall. However,
the small molecule lacks the interaction with Lys58 that
GM establishes through its methoxy group on the benzo-
quinone (Fig. 3D). This would probably result in a lower
a⁄nity of PU3 for Hsp90 and points for future improve-
ments of the PU3 molecule.
The ‘rule of 5’ of Lipinsky [18] predicts that this mole-
cule should have acceptable pharmacokinetics. PU3 has
one hydrogen bond donor, the sum of Ns and Os is 8,
has a molecular weight of 371 and a M log P value of 2.2.
This suggests that PU3 is a reasonable starting point for
the development of bioavailable drugs.
2.2. PU3 binds to Hsp90 in vitro
GM and RD were shown to bind full-length dimeric
Hsp90 with Kds of 1.2 WM and 19 nM, respectively [16].
We determined the concentration of PU3 required to com-
pete with GM for Hsp90 binding in order to obtain a
relative binding a⁄nity for this compound. GM was im-
mobilized on A⁄gel 10 resin (Bio-Rad) via a method
slightly modi¢ed from described. [19]. Preincubation of
puri¢ed Hsp90 with PU3 inhibited binding of the protein
to immobilized GM with an EC50 of 15^20 WM, whereas
only about 1 WM of 17AAG was required under similar
conditions (Fig. 4B). These numbers suggest that our de-
signed ¢rst generation inhibitor binds to Hsp90 K at an
a⁄nity approximately 20-fold weaker than does 17AAG.
ADP and the control compound Ad-But, a molecule that
lacks the trimethoxybenzyl moiety of PU3, exhibited no
activity at similar concentrations (Fig. 4C). More than 4.5
mM ADP was necessary to compete with GM for 50% of
Hsp90 binding. Rabbit reticulocyte lysates were addition-
Fig. 4. PU3 competes with GM for Hsp90 binding. Hsp90 protein was incubated with GM a⁄nity beads and its binding to the immobilized GM was
competed with increased concentrations of PU3 (A), ADP and Ad-But (C). Data obtained from image analysis of the competition of Hsp90 K by PU3,
17AAG and ADP were graphed as shown in B. (D) Rabbit reticulocyte lysate was used as source of protein and Hsp90 L binding to the GM beads
was assessed. U = base-line binding of Hsp90 to the GM beads.
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ally employed as a source of Hsp90 proteins for competi-
tion assays (Fig. 4D) demonstrating that PU3 is a poten-
tial inhibitor of both Hsp90 K and L.
The 4-methoxy functionality of PU3 points outside the
pocket when the molecule is bound to Hsp90 (Fig. 3).
Molecular modeling suggests that a modi¢cation at that
position will still allow binding to the pocket. Therefore, a
biotinylated PU3 (PU3-B) was constructed (Fig. 5A) and
attached to a streptavidin solid support to study whether
this molecule is able to a⁄nity immobilize the members of
the Hsp90 family. The molecule speci¢cally binds to
Hsp90 and Trap-1 as well as the N-terminal fragment of
Grp94 that contains the ADP/ATP binding pocket (Fig.
5B,C).
2.3. PU3 depletes cancer cells of Hsp90-dependent signaling
proteins
GM binding to Hsp90 a¡ects the function and stability
of steroid receptors and certain signaling proteins includ-
ing Raf1 and Her2. PU3 a¡ects this subset of proteins in a
similar fashion (Fig. 6). As expected, PU3 destabilizes the
estrogen receptor complexes and induces dose-dependent
degradation of the protein (Fig. 6A). The tyrosine kinase
Her2 is one of the most sensitive targets of GM. PU3
causes a rapid decrease in Her2 levels ; more than 50%
of Her2 is degraded less than 3 h after drug treatment
(Fig. 6B). Addition of PU3 causes degradation of Her2
in both MCF-7, a breast cancer cell line with moderate
Her2 expression, as well as in SKBr3, a Her2 overexpress-
ing line. The e¡ects are seen at doses as low as 10 WM
(Fig. 6A). Like GM, PU3 causes the accumulation of a
lower migrating band that is thought to represent incom-
pletely glycosylated Her2 sequestered in the endoplasmic
reticulum (170 kDa vs. 180 kDa mature Her2). However,
the levels of Raf1 and Her3 are less sensitive and more
than 50 WM drug is necessary to bring these proteins to
basal levels. The control derivatives Ad-But (Fig. 6C) and
PU3R (data not shown) had no e¡ect on Her2 or Raf1
levels at similar concentrations. The set of proteins de-
graded by PU3 is limited to those sensitive to GM. The
compound has no e¡ect on the levels of tubulin, PI3 ki-
nase (PI3K) (p85 unit) and L-actin, proteins also unaf-
fected by GM and RD.
2.4. PU3 induces the synthesis of Hsp90
It is known that ansamycins induce the synthesis of
Hsp90 and Hsp70 [19,20] and we observe the same
phenomena following treatment of MCF-7 cells with
PU3. Treatment of cells with 17AAG induces a pro-
tein band that migrates more rapidly than Trap-1 and
that is recognized by an anti-Trap-1 antibody (Fig. 7A).
A similar e¡ect is observed after PU3 addition, but
not with the control PU3 isomer, PU3R (Fig. 7B).
Although the identity of this protein band is unknown,
Fig. 5. A⁄nity immobilization of Hsp90, Trap-1 and Grp94 N-terminal (1^355) by PU3. (A) Structure of the PU3-biotin derivative. (B and C) An in-
creasing amount of PU3-B was used with a constant amount of streptavidin beads and protein. Speci¢city of binding is demonstrated by the absence in
binding of proteins to the streptavidin-biotin beads alone and competition of binding by ADP and not GDP. Control = speci¢c protein loaded as
marker (amounts di¡er). B = biotin.
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Fig. 7. PU3, like GM, increases the cellular levels of Hsp90 and Hsp70. (A) MCF-7 cells were treated with increasing concentrations of drug for 24 h.
Protein levels were assessed by Western blotting. (B) Time-dependent e¡ect of PU3 (100 WM) on protein levels in MCF-7 cell line. (C) The control pu-
rine PU3R, an isomer of PU3, has no e¡ect on the studied protein levels at identical concentrations.
Fig. 6. PU3 induces the degradation of a subset of proteins in the MCF-7 and SKBr3 breast cancer cells in a fashion similar to GM. (A) MCF-7 and
SKBr3 cells were treated with increasing concentrations of drug for 24 h. (B) Time-dependent degradation of Her2 and Raf1 in the MCF-7 cell line by
addition of 100 WM PU3. (C) The control Ad-But has no e¡ect on these proteins at similar doses. (D) PU3 has no e¡ect on protein levels involved in
di¡erent signaling pathways.
CHBIOL 80 5-4-01 Cyaan Magenta Geel Zwart
294 Chemistry & Biology 8/3 (2001) 289^299
its appearance seems to be a marker of cellular exposure
to ansamycins.
2.5. In vitro antiproliferative activity of PU3
We examined the e¡ect of PU3 on the growth of three
breast cancer cell lines: MCF-7, SKBr3 and MDA-MB-
468. The compound showed antiproliferative e¡ects at low
micromolar concentrations similar to those that compete
for Hsp90 binding and induce protein degradation (Fig. 8).
2.6. PU3 arrests breast cancer cells in G1
Breast cancer cells treated with PU3 arrest in the G1
Fig. 8. Antiproliferative e¡ects of PU3 and the control compound Ad-But on MCF-7, SKBr3 and MDA-MB-468 breast cancer cell lines.
Fig. 9. (A) 100 WM PU3 causes predominantly G1 block associated with (B) reduction in cyclin D1 expression and Rb hypophosphorylation in the
breast cancer cell lines MCF-7 and SKBr3.
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phase of the cell cycle and the process is associated with
hypophosphorylation of the retinoblastoma protein (Rb)
and reduction in D-cyclin expression (Fig. 9). We have
previously shown that ansamycins induce the Rb-depen-
dent G1 arrest of epithelial cancer cells [21]. The mecha-
nism of the G1 arrest in breast cancer cells that overex-
press Her2 involves down regulation of a Her2-initiated,
PI3K- and akt kinase-dependent pathway that is required
for e⁄cient expression of cyclin D. This results in rapid
reduction of D-cyclin-associated kinase activity and G1
arrest. PU3 causes a similar phenotype (Fig. 9A). The
compound causes predominantly G1 block associated
with Rb hypophosphorylation at 12 h after treatment
and a rapid decrease in cyclin D levels (3^6 h after treat-
ment) (Fig. 9B).
2.7. Induction of morphologic and functional di¡erentiation
In breast cancer cells treated with ansamycins, G1 block
is followed by morphological and functional di¡erentia-
tion.
MCF-7 cells are round with scanty eosinophilic cyto-
plasm, indistinct cell margins and contain the prominent
nucleoli characteristic of cancer cells. They express mini-
mal levels of milk fat proteins and contain few fat-con-
taining vacuoles or other features of mammary di¡erentia-
tion. Cells exposed to PU3 £atten, increase in size and
have distinct cellular boundaries. These morphological
changes are characteristic of mature epithelial di¡erentia-
tion and reversal of transformation (Fig. 10A).
The milk fat globule membrane protein (MFGM) is a
component of the milk fat globule membrane, a structure
that surrounds the milk fat in breast cells. Breast cancer
cells express this protein at low levels, however, addition
of 17AAG, a derivative of GM, induces the expression of
the protein in the MCF-7 and SKBr3 cell lines [25]. The
same phenomenon was observed upon addition of PU3 to
the MCF-7 line (Fig. 10B).
The induction of a G1 arrest by a variety of manipula-
tions is su⁄cient for induction of expression of some
milk proteins. However, only ansamycins and the HDAC
inhibitor SAHA cause extensive morphological and bio-
chemical changes [25]. We found that the morphological
phenotype induced by PU3 is very similar to 17AAG
and thus, PU3 is likely to function by the same mecha-
nism.
Fig. 10. (A) PU3 induces MFGM protein in MCF-7 cells. MFGM protein was detected with an anti-MFGM antibody and a rhodamine- (red) labeled
secondary antibody. Nuclear DNA was stained with DAPI. (B) PU3 induces signi¢cant morphological di¡erentiation in the MCF-7 line. Cells were
stained with HpE.
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3. Conclusions
We have used the structure of the co-crystals of Hsp90
and its ligands (GM, RD and adenine nucleotides) to de-
sign a novel compound that interacts with the Hsp90^nu-
cleotide binding pocket. The compound competes with
GM for binding to Hsp90 K with a relative a⁄nity of
15^20 WM, a potency that is proportional to its e⁄cacy
in inducing cellular e¡ects. Addition of PU3 to cells causes
the degradation of HER kinases, estrogen receptor and
Raf kinase. Control proteins such as PI3K, tubulin and
L-actin are una¡ected. The proteins a¡ected by PU3 are
identical to those a¡ected by ansamycins. Exposure of
breast cancer cells to PU3 results in growth inhibition
and profound morphologic changes. Growth inhibition
results from arrest in the G1 phase of the cell cycle and
is associated with reduction in D-cyclin expression and
hypophosphorylation of the Rb protein. Cessation of pro-
liferation is accompanied by induction of a more mature,
epithelial morphology consistent with breast di¡erentia-
tion. The qualitative e¡ects of PU3 on cellular protein
expression, proliferation, and di¡erentiation are very sim-
ilar to those induced by GM and RD. We concluded that
in PU3 we have successfully designed a compound that
binds to the Hsp90 family pocket and elicits its biologic
e¡ects by regulating the function of these proteins. It is
possible that PU3 also interacts with other proteins that
contain a similar pocket, such as DNA gyrase or MutL.
However, considering the weak homology these proteins
have with the Hsp90s, this is unlikely to happen at low
drug concentrations.
Taken together, the data suggest that the biologic e¡ects
of PU3 and ansamycins are overlapping and result from
occupancy of the conserved pocket in Hsp90 family pro-
teins.
4. Signi¢cance
The Hsp90 family of chaperones plays a key role in
regulating the physiology of cells exposed to environmen-
tal stress and in maintaining the malignant phenotype in
tumor cells. The function of these proteins may be modu-
lated with compounds that bind to a conserved binding
pocket in the amino-terminus of the protein. We have now
designed and synthesized a compound, PU3, that binds to
this pocket and shares the biologic properties of its natural
product ligands. Development of a family of such com-
pounds may allow the selection and identi¢cation of mol-
ecules that interact speci¢cally with individual members of
the Hsp90 family. Such reagents will be useful probes with
which to study the individual members of the Hsp90 fam-
ily and have potential utility as drugs.
Both ansamycins and PU3 cause the degradation of a
subset of key signaling proteins and inhibit the prolifera-
tion of human cancer cells. The Her2 transmembrane ty-
rosine kinase is one of the most sensitive targets of these
drugs. Her2 has oncogenic properties and is overexpressed
in many human tumors, including approximately 30% of
human breast cancers. Recently, an anti-Her2 antibody
was shown to have limited therapeutic utility in these pa-
tients when given alone or in combination with cytotoxic
chemotherapy. Breast cancer cells that express high levels
of Her2 are quite sensitive to PU3 and 17AAG. The an-
samycin derivative, 17AAG, is currently in early clinical
trial in cancer patients. 17AAG is a potent anti-cancer
drug, but it is poorly soluble, obtainable only by fermen-
tation, and induces toxicities that are probably unrelated
to Hsp90 binding. PU3 is less potent, but it is a ¢rst gen-
eration lead compound. It is likely that further medicinal
chemistry will yield derivatives with increased binding af-
¢nity and activity. Moreover, PU3 is soluble, easily syn-
thesized, and may be less toxic and adaptable to oral ad-
ministration. The development of this novel class of small
molecules that induces the destruction of Her2 could lead
to a new method for the treatment of advanced breast
cancer.
5. Materials and methods
PU3 and the control molecules were synthesized as described
[22]. Trap-1 protein was a gift from Dr. Sara Felts and the N-
terminal domain of Grp94 (1^355) was kindly provided by Dr.
Shawn Vogen (Dr. Argon Yair’s laboratory).
5.1. Computer modeling
The designed molecules were manually docked in the N-termi-
nal Hsp90 K ADP/ATP binding pocket (Protein Data Bank code
1YET) and the complexes were minimized using the generalized
born/surface area solvation method for water and AMBER*
force ¢eld as implemented in version 6.5 Macromodel.
5.2. Immobilization of GM
To 2 ml of wet beads (Bio-Rad, A⁄gel 10) in 2 ml CH2Cl2
was added 50 mg of 1,4-diaminobutane and the mixture was
shaken for 2 h at room temperature (RT). The beads were
washed with 3U5 ml CH2Cl2/triethylamine (TEA) = 9:1, 3U5
ml DMF, 3U5 ml 2-PrOH and 1U5 ml DMF, followed by ad-
dition of 17 mg GM and 10 Wl TEA in 1 ml DMF. The slurry was
rotated overnight and then washed with 2U5 ml CH2Cl2, 2U5
ml 2-PrOH and again 2U5 ml CH2Cl2. The unreacted amines
were capped by addition of excess Ac2O^TEA in 1 ml CH2Cl2
(until no positive ninhydrin test, about 15^25 min). After exten-
sive washes with 4U5 ml CH2Cl2 and 4U5 ml 2-PrOH, the GM
beads were rotated overnight in 2-PrOH to allow for signi¢cant
swelling and then washed and transferred to the appropriate bu¡-
er.
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5.3. Hsp90 competition
The GM beads were blocked for 1 h at 4‡C with 0.5% bovine
serum albumin (BSA) in TEN bu¡er (50 mM Tris^HCl pH 7.4,
1 mM EDTA, 1% NP-40) prior to use. Hsp90 protein (Stressgen)
(0.2 Wg) or 2 Wl of rabbit reticulocyte lysate (Promega) was in-
cubated with or without drugs for 15 min on ice. To each sample
were added 20 Wl GM beads (wet volume) and the mixtures were
rotated at 4‡C for 1 h followed by two washes with 500 Wl ice-
cold TEN each. The GM beads-bound protein was eluted from
the solid phase by heating in 35 Wl 1Usodium dodecyl sulfate
(SDS), analyzed by SDS^PAGE and visualized by immunoblot-
ting with Hsp90 K (Stressgen #SPA-840) or Hsp90 L (Neo-
markers) antibodies.
5.4. Preparation and use of the PU3-biotin molecule
PU3-biotin was assembled by selective deprotection of the
4-methoxy functionality of PU3 using L-bromo-9-BBN, followed
by addition of an intermediate linker via a Mitsunobu reaction
and ¢nally, biotin was introduced by formation of an amide bond
between the product and EZ-Link1 NHS-LC-Biotin (Pierce
#21336). PU3-biotin was suspended in DMSO to yield a 100
mM solution. A volume of 1, 2 or 3 Wl of this solution was added
to 80 Wl slurry (50% solution) of Sepharose-streptavidin (Zymed
#43-4341) in phosphate-bu¡ered saline (PBS) and incubated at
RT for 20 min. The beads were washed extensively with 1UPBS^
0.2% Tween, 1UPBS containing protease inhibitors, followed by
2UPBS^0.2% Tween. To the wet beads was added 0.3 Wg protein
in 40 Wl RSBT bu¡er (10 mM Tris, pH 7.4, 10 mM NaCl, 1.5
mM MgCl2, 0.1% Tween) and the mix was incubated for 1 h at
4‡C. The unbound protein was removed by washing with PBS^
0.2% Tween. Proteins bound to the a⁄nity matrix were eluted by
boiling in 60 Wl 1USDS and separated by 10% SDS^PAGE.
After transfer to nitrocellulose, the membranes were probed
with anti-Trap-1 (MSK81), anti-Hsp90 K (Stressgen #SPA-840)
and anti-Grp94 (Stressgen #SPA-850).
5.5. Cell culture
The human cancer cell lines MCF-7, SKBr3 and MDA-MB-
468 were obtained from the American Type Culture Collection
(Manassas, VA, USA) and maintained in 1:1 mixture of
DME:F12 supplemented with 2 mM glutamine, 50 U/ml penicil-
lin, 50 U/ml streptomycin and 5% (for MCF-7 and MDA-MB-
468) or 10% (for SKBr3) heat-inactivated fetal bovine serum
(Gemini Bioproducts) and incubated at 37‡C in 5% CO2.
5.6. Protein assays
Cells were grown to 60^70% con£uence and exposed to drugs
or DMSO vehicle for the indicated time periods. Lysates were
prepared using 50 mM Tris pH 7.4, 2% SDS and 10% glycerol
lysis bu¡er. Protein concentration was determined using the BCA
kit (Pierce Chemical Co.), according to the manufacturer’s in-
structions. Clari¢ed protein lysates (20^50 Wg) were electrophor-
etically resolved on denaturing SDS^PAGE, transferred to nitro-
cellulose and probed with the following primary antibodies:
anti-Her2 (C-18), -Her3 (C-17), -Raf1, -cyclin D1, -Rb (C-15)
(Santa Cruz), anti-Hsp90, -Hsp70, -ER (Stressgen), anti-Trap-1
(MSK81), anti-L-actin, -tubulin (Sigma), anti-PI3K (p85) (Up-
state Biotechnologies).
5.7. Antiproliferative index
Growth assays were performed by seeding 10 000 cells (MCF-7
and MDA-MB-468) and 20 000 cells (SKBr3) per well in 6-well
dishes and incubating for 24 h before drug treatment. Drugs or
vehicle were administered as outlined for each experiment, and
cells were incubated for the time periods depicted and then the
number quanti¢ed by a Coulter counter.
5.8. Flow cytometry
Cell cycle distribution was assayed according to Nusse et al.
[23] with a Becton Dickinson £uorescence-activated cell sorter
and analyzed by a Cell Cycle Multi-cycle system (Phoenix Flow
System, San Diego, CA, USA).
5.9. Immuno£uorescence (IF) and hematoxylin and eosin stain
(HpE)
Cells were plated 5000 cells/chamber slide (¢bronectin-coated
Lab-Tek 2 well chamber slides, Fisher Scienti¢c) and seeded for
24 h. Drugs or vehicle were added for 5 days after which, for IF,
the slides were washed twice with ice-cold PBS and ¢xed with
methanol and acetone solution (1:1) for 15 s. Fixed monolayers
were washed with distilled water and blocked with 5% BSA in
PBS solution. After blocking, cells were incubated with the pri-
mary antibody (anti-MFMG, Chemicon, 1:100 in 5% BSA in
PBS) at 37‡C and washed three times with 1% BSA in PBS,
followed by incubation with a rhodamine-labeled secondary anti-
body for 1 h at 37‡C. Nuclei were stained with DAPI at 1 Wg/ml.
For HpE, the cells were ¢xed with paraformaldehyde (4%) for 10
min at RT and stained according to standard HpE staining pro-
tocols [24].
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